speb/financial-data huggingface dataset:
SYRE income_statement (annual, 2024-12-31) — Normalized Income: -208018000.00
SYRE cash_flow (annual, 2024-12-31) — Operating Cash Flow: -157410000.00
SYRE income_statement (annual, 2024-12-31) — Operating Income: -208566000.00
SYRE income_statement (annual, 2024-12-31) — Operating Revenue: 0.00
SYRE balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 60257023.00
SYRE balance_sheet (annual, 2024-12-31) — Other Current Assets: 5386000.00
SYRE balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 25581000.00
SYRE balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: 180000.00
SYRE income_statement (annual, 2024-12-31) — Other Gand A: 45776000.00
SYRE income_statement (annual, 2024-12-31) — Other Income Expense: -20713000.00
SYRE cash_flow (annual, 2024-12-31) — Other Non Cash Items: 20430000.00
SYRE balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 10000.00
SYRE balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: 10000.00
SYRE balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 36620000.00
SYRE balance_sheet (quarterly, 2024-12-31) — Other Non Current Liabilities: 36620000.00
SYRE income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -20713000.00
SYRE balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 513665000.00
SYRE balance_sheet (annual, 2024-12-31) — Payables: 1269000.00
SYRE balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 22791000.00
SYRE balance_sheet (annual, 2024-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 5688000.00
SYRE balance_sheet (annual, 2024-12-31) — Preferred Securities Outside Stock Equity: 0.00
SYRE balance_sheet (quarterly, 2024-12-31) — Preferred Securities Outside Stock Equity: 0.00
SYRE balance_sheet (annual, 2024-12-31) — Preferred Stock: 155820000.00
SYRE income_statement (annual, 2024-12-31) — Preferred Stock Dividends: 58463000.00
SYRE balance_sheet (annual, 2024-12-31) — Preferred Stock Equity: 155820000.00
SYRE cash_flow (annual, 2024-12-31) — Preferred Stock Issuance: 168850000.00
SYRE cash_flow (quarterly, 2024-12-31) — Preferred Stock Issuance: 0.00
SYRE income_statement (annual, 2024-12-31) — Pretax Income: -207967000.00
SYRE cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 7511000.00
SYRE cash_flow (annual, 2024-12-31) — Purchase Of Investment: -599252000.00
SYRE cash_flow (annual, 2024-12-31) — Purchase Of PPE: 0.00
SYRE income_statement (annual, 2024-12-31) — Reconciled Depreciation: 0.00
SYRE income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 0.00
SYRE cash_flow (annual, 2024-12-31) — Repayment Of Debt: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Repayment Of Debt: 0.00
SYRE income_statement (annual, 2024-12-31) — Research And Development: 162790000.00
SYRE balance_sheet (annual, 2024-12-31) — Retained Earnings: -972432000.00
SYRE cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Sale Of Business: 0.00
SYRE cash_flow (annual, 2024-12-31) — Sale Of Intangibles: 0.00
SYRE cash_flow (annual, 2024-12-31) — Sale Of Investment: 245967000.00
SYRE cash_flow (annual, 2024-12-31) — Sale Of PPE: 0.00
SYRE cash_flow (quarterly, 2024-12-31) — Sale Of PPE: 0.00
SYRE income_statement (annual, 2024-12-31) — Selling General And Administration: 45776000.00
SYRE balance_sheet (annual, 2024-12-31) — Share Issued: 60257023.00
SYRE income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
SYRE cash_flow (annual, 2024-12-31) — Stock Based Compensation: 44833000.00
SYRE balance_sheet (annual, 2024-12-31) — Stockholders Equity: 517804000.00
SYRE balance_sheet (annual, 2024-12-31) — Tangible Book Value: 361984000.00
SYRE income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (annual, 2024-12-31) — Tax Provision: 51000.00
SYRE income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
SYRE balance_sheet (annual, 2024-12-31) — Total Assets: 608484000.00
SYRE balance_sheet (annual, 2024-12-31) — Total Capitalization: 517804000.00
SYRE balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 517804000.00
SYRE income_statement (annual, 2024-12-31) — Total Expenses: 208566000.00
SYRE balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 90680000.00
SYRE balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 10000.00
SYRE balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 36620000.00
SYRE income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -208566000.00
SYRE income_statement (annual, 2024-12-31) — Total Unusual Items: 0.00
SYRE income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
SYRE balance_sheet (annual, 2024-12-31) — Working Capital: 554414000.00
SYRE income_statement (quarterly, 2025-03-31) — +Operating Expense: 53567000.00
SYRE income_statement (quarterly, 2025-03-31) — +Total Revenue: 0.00
SYRE balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 3689000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1343300000.00
SYRE cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: -2642000.00
SYRE income_statement (quarterly, 2025-03-31) — Basic Average Shares: 60265932.00
SYRE income_statement (quarterly, 2025-03-31) — Basic EPS: -0.60
SYRE cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 89423000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Capital Stock: 155833000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 48493000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 564820000.00
SYRE cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 125000.00
SYRE cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -61000.00
SYRE cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: -40994000.00
SYRE cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 4968000.00
SYRE cash_flow (quarterly, 2025-03-31) — Change In Accrued Expense: -5998000.00
SYRE cash_flow (quarterly, 2025-03-31) — Change In Payable: 4968000.00
SYRE cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -1030000.00
SYRE cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 462000.00
SYRE cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -568000.00
SYRE cash_flow (quarterly, 2025-03-31) — Changes In Cash: -40930000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Common Stock: 13000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 326790000.00
SYRE cash_flow (quarterly, 2025-03-31) — Common Stock Issuance: 0.00
SYRE cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -117000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 19699000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Current Assets: 569768000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 70678000.00
SYRE income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 60265932.00
SYRE income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.60
SYRE income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -44773000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Dueto Related Parties Current: 2548000.00
SYRE income_statement (quarterly, 2025-03-31) — EBIT: -53567000.00
SYRE income_statement (quarterly, 2025-03-31) — EBITDA: -53567000.00
SYRE cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 0.00
SYRE cash_flow (quarterly, 2025-03-31) — End Cash Position: 48493000.00
SYRE cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 125000.00
SYRE cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -40994000.00
SYRE cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of PPE: 0.00
SYRE income_statement (quarterly, 2025-03-31) — Gain On Sale Of Ppe: 0.00
SYRE balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 682000.00
SYRE income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 11944000.00
SYRE income_statement (quarterly, 2025-03-31) — Interest Income: 6493000.00
SYRE income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 6493000.00
SYRE cash_flow (quarterly, 2025-03-31) — Interest Received Cfo: 530000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Invested Capital: 326790000.00
SYRE cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -61000.00
SYRE cash_flow (quarterly, 2025-03-31) — Issuance Of Capital Stock: 0.00
SYRE cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: 0.00
SYRE income_statement (quarterly, 2025-03-31) — Net Income: -44773000.00
SYRE income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -44773000.00
SYRE income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -44773000.00
SYRE income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -44773000.00
SYRE income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -44773000.00
SYRE cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -44773000.00
SYRE income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -44773000.00
SYRE cash_flow (quarterly, 2025-03-31) — Net Intangibles Purchase And Sale: 0.00
SYRE income_statement (quarterly, 2025-03-31) — Net Interest Income: 6493000.00
SYRE cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -61000.00
SYRE income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 6493000.00
SYRE cash_flow (quarterly, 2025-03-31) — Net Other Financing Charges: -93000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 482610000.00
SYRE income_statement (quarterly, 2025-03-31) — Normalized EBITDA: -53567000.00
SYRE income_statement (quarterly, 2025-03-31) — Normalized Income: -44773000.00
SYRE cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: -40994000.00
SYRE income_statement (quarterly, 2025-03-31) — Operating Income: -53567000.00
SYRE income_statement (quarterly, 2025-03-31) — Operating Revenue: 0.00
SYRE balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 60275561.00
SYRE balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 4948000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 43181000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 682000.00
SYRE income_statement (quarterly, 2025-03-31) — Other Gand A: 11944000.00
SYRE income_statement (quarterly, 2025-03-31) — Other Income Expense: 2286000.00
SYRE cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: -2400000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 10000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 16490000.00
SYRE income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 2286000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 516327000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Payables: 6237000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 25936000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 1561000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 155820000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Preferred Stock Equity: 155820000.00
SYRE income_statement (quarterly, 2025-03-31) — Pretax Income: -44788000.00
SYRE cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 218000.00
SYRE cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -71444000.00
SYRE cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -117000.00
SYRE income_statement (quarterly, 2025-03-31) — Research And Development: 41623000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Retained Earnings: -1017205000.00
SYRE cash_flow (quarterly, 2025-03-31) — Sale Of Intangibles: 0.00
SYRE cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 71383000.00
SYRE income_statement (quarterly, 2025-03-31) — Selling General And Administration: 11944000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Share Issued: 60275561.00
SYRE income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
SYRE cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 8859000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 482610000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 326790000.00
SYRE income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (quarterly, 2025-03-31) — Tax Provision: -15000.00
SYRE income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.00
SYRE balance_sheet (quarterly, 2025-03-31) — Total Assets: 569778000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 482610000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 482610000.00
SYRE income_statement (quarterly, 2025-03-31) — Total Expenses: 53567000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 87168000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 10000.00
SYRE balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 16490000.00
SYRE income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -53567000.00
SYRE income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
SYRE income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
SYRE balance_sheet (quarterly, 2025-03-31) — Working Capital: 499090000.00
SYRE income_statement (quarterly, 2025-06-30) — +Operating Expense: 51935000.00
SYRE income_statement (quarterly, 2025-06-30) — +Total Revenue: 0.00
SYRE balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 3712000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1353408000.00
SYRE cash_flow (quarterly, 2025-06-30) — Amortization Of Securities: -2013000.00
SYRE income_statement (quarterly, 2025-06-30) — Basic Average Shares: 60696550.00
SYRE income_statement (quarterly, 2025-06-30) — Basic EPS: -0.60
SYRE cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 48493000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Capital Stock: 155833000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 81659000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 526580000.00
SYRE cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 731000.00
SYRE cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 78998000.00
SYRE cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -46563000.00
SYRE cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -1922000.00
SYRE cash_flow (quarterly, 2025-06-30) — Change In Accrued Expense: -2301000.00
SYRE cash_flow (quarterly, 2025-06-30) — Change In Payable: -2494000.00
SYRE cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -4795000.00
SYRE cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: -4246000.00
SYRE cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -9041000.00
SYRE cash_flow (quarterly, 2025-06-30) — Changes In Cash: 33166000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Common Stock: 13000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 299953000.00
SYRE cash_flow (quarterly, 2025-06-30) — Common Stock Issuance: 0.00
SYRE cash_flow (quarterly, 2025-06-30) — Common Stock Payments: 0.00
SYRE balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 15885000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Current Assets: 538832000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 83059000.00
SYRE income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 60696550.00
SYRE income_statement (quarterly, 2025-06-30) — Diluted EPS: -0.60
SYRE income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: -36717000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Dueto Related Parties Current: 31000.00
SYRE income_statement (quarterly, 2025-06-30) — EBIT: -51935000.00
SYRE income_statement (quarterly, 2025-06-30) — EBITDA: -51935000.00
SYRE cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 0.00
SYRE cash_flow (quarterly, 2025-06-30) — End Cash Position: 81659000.00
SYRE cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 731000.00
SYRE cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -46563000.00
SYRE cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of PPE: -10000000.00
SYRE income_statement (quarterly, 2025-06-30) — Gain On Sale Of Ppe: 10000000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 454000.00
SYRE income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 11790000.00
SYRE income_statement (quarterly, 2025-06-30) — Interest Income: 5874000.00
SYRE income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 5874000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Invested Capital: 299953000.00
SYRE cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 78998000.00
SYRE cash_flow (quarterly, 2025-06-30) — Issuance Of Capital Stock: 0.00
SYRE cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -117000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Income: -36717000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: -36717000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: -36717000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: -36717000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: -36717000.00
SYRE cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: -36717000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: -36717000.00
SYRE cash_flow (quarterly, 2025-06-30) — Net Intangibles Purchase And Sale: 7000000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Interest Income: 5874000.00
SYRE cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 71998000.00
SYRE income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 5874000.00
SYRE cash_flow (quarterly, 2025-06-30) — Net Other Financing Charges: 0.00
SYRE balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 455773000.00
SYRE income_statement (quarterly, 2025-06-30) — Normalized EBITDA: -61935000.00
SYRE income_statement (quarterly, 2025-06-30) — Normalized Income: -46717000.00
SYRE cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -46563000.00
SYRE income_statement (quarterly, 2025-06-30) — Operating Income: -51935000.00
SYRE income_statement (quarterly, 2025-06-30) — Operating Revenue: 0.00
SYRE balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 60372927.00
SYRE balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 12252000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 60142000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 454000.00
SYRE income_statement (quarterly, 2025-06-30) — Other Gand A: 11790000.00
SYRE income_statement (quarterly, 2025-06-30) — Other Income Expense: 9344000.00
SYRE cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 2360000.00
SYRE income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: -656000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 444921000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Payables: 3743000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 19628000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Pensionand Other Post Retirement Benefit Plans Current: 3289000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 155820000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Preferred Stock Equity: 155820000.00
SYRE income_statement (quarterly, 2025-06-30) — Pretax Income: -36717000.00
SYRE cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 848000.00
SYRE cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -34868000.00
SYRE cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: 0.00
SYRE income_statement (quarterly, 2025-06-30) — Research And Development: 40145000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -1053922000.00
SYRE cash_flow (quarterly, 2025-06-30) — Sale Of Intangibles: 7000000.00
SYRE cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 106866000.00
SYRE income_statement (quarterly, 2025-06-30) — Selling General And Administration: 11790000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Share Issued: 60372927.00
SYRE income_statement (quarterly, 2025-06-30) — Special Income Charges: 10000000.00
SYRE cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 9378000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 455773000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 299953000.00
SYRE income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (quarterly, 2025-06-30) — Tax Provision: 0.00
SYRE income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
SYRE balance_sheet (quarterly, 2025-06-30) — Total Assets: 538832000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 455773000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 455773000.00
SYRE income_statement (quarterly, 2025-06-30) — Total Expenses: 51935000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 83059000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 0.00
SYRE balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 0.00
SYRE income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -41935000.00
SYRE income_statement (quarterly, 2025-06-30) — Total Unusual Items: 10000000.00
SYRE income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 10000000.00
SYRE balance_sheet (quarterly, 2025-06-30) — Working Capital: 455773000.00
SYRE income_statement (quarterly, 2025-09-30) — +Operating Expense: 56888000.00
SYRE income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 7457000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1363581000.00
SYRE cash_flow (quarterly, 2025-09-30) — Amortization Of Securities: -1350000.00
SYRE income_statement (quarterly, 2025-09-30) — Basic Average Shares: 60776935.00
SYRE income_statement (quarterly, 2025-09-30) — Basic EPS: -0.18
SYRE cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 81659000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Capital Stock: 155833000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 64897000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 486198000.00
SYRE cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -4643000.00
SYRE cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: 24998000.00
SYRE cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -37117000.00
SYRE cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 3745000.00
SYRE cash_flow (quarterly, 2025-09-30) — Change In Accrued Expense: 4411000.00
SYRE cash_flow (quarterly, 2025-09-30) — Change In Payable: 7684000.00
SYRE cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 12095000.00
SYRE cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -6155000.00
SYRE cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 5940000.00
SYRE cash_flow (quarterly, 2025-09-30) — Changes In Cash: -16762000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Common Stock: 13000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 299280000.00
SYRE cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 18525000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Current Assets: 504604000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 46274000.00
SYRE income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 60776935.00
SYRE income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.18
SYRE income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -11183000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Dueto Related Parties Current: 3970000.00
SYRE income_statement (quarterly, 2025-09-30) — EBIT: -56888000.00
SYRE income_statement (quarterly, 2025-09-30) — EBITDA: -56888000.00
SYRE cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 0.00
SYRE cash_flow (quarterly, 2025-09-30) — End Cash Position: 64897000.00
SYRE cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -4643000.00
SYRE cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -37117000.00
SYRE cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of PPE: 0.00
SYRE income_statement (quarterly, 2025-09-30) — Gain On Sale Of Ppe: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 791000.00
SYRE income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 11641000.00
SYRE income_statement (quarterly, 2025-09-30) — Interest Income: 5379000.00
SYRE income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 5379000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Invested Capital: 299280000.00
SYRE cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: 24998000.00
SYRE cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 0.00
SYRE cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 117000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Income: -11183000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -11183000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -11183000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -11183000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -11183000.00
SYRE cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -11183000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -11183000.00
SYRE cash_flow (quarterly, 2025-09-30) — Net Intangibles Purchase And Sale: 0.00
SYRE income_statement (quarterly, 2025-09-30) — Net Interest Income: 5379000.00
SYRE cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 24998000.00
SYRE income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 5379000.00
SYRE cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -5251000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 455100000.00
SYRE income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -56888000.00
SYRE income_statement (quarterly, 2025-09-30) — Normalized Income: -11183000.00
SYRE cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -37117000.00
SYRE cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 0.00
SYRE income_statement (quarterly, 2025-09-30) — Operating Income: -56888000.00
SYRE income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 60471793.00
SYRE balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 18406000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 11190000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 791000.00
SYRE income_statement (quarterly, 2025-09-30) — Other Gand A: 11641000.00
SYRE income_statement (quarterly, 2025-09-30) — Other Income Expense: 40326000.00
SYRE cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: -42159000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: 3230000.00
SYRE income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 40326000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 421301000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Payables: 11427000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 29952000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Pensionand Other Post Retirement Benefit Plans Current: 5132000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 155820000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Preferred Stock Equity: 155820000.00
SYRE income_statement (quarterly, 2025-09-30) — Pretax Income: -11183000.00
SYRE cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 491000.00
SYRE cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -74193000.00
SYRE income_statement (quarterly, 2025-09-30) — Research And Development: 45247000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -1065105000.00
SYRE cash_flow (quarterly, 2025-09-30) — Sale Of Intangibles: 0.00
SYRE cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 99191000.00
SYRE income_statement (quarterly, 2025-09-30) — Selling General And Administration: 11641000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Share Issued: 60471793.00
SYRE income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
SYRE cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 9566000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 455100000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 299280000.00
SYRE income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (quarterly, 2025-09-30) — Tax Provision: 0.00
SYRE income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Total Assets: 504604000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 455100000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 455100000.00
SYRE income_statement (quarterly, 2025-09-30) — Total Expenses: 56888000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 49504000.00
SYRE balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 3230000.00
SYRE income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -56888000.00
SYRE income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
SYRE income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
SYRE balance_sheet (quarterly, 2025-09-30) — Working Capital: 458330000.00
SYRE income_statement (annual, 2025-12-31) — +Operating Expense: 219562000.00
SYRE income_statement (quarterly, 2025-12-31) — +Operating Expense: 57172000.00
SYRE income_statement (annual, 2025-12-31) — +Total Revenue: 0.00
SYRE income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Accounts Payable: 8904000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 8904000.00
SYRE balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1686167000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1686167000.00
SYRE cash_flow (annual, 2025-12-31) — Amortization Of Securities: -8090000.00
SYRE cash_flow (quarterly, 2025-12-31) — Amortization Of Securities: -2085000.00
SYRE cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 0.00
SYRE income_statement (annual, 2025-12-31) — Basic Average Shares: 64056442.00
SYRE income_statement (quarterly, 2025-12-31) — Basic Average Shares: 75088910.00
SYRE income_statement (annual, 2025-12-31) — Basic EPS: -1.98
SYRE income_statement (quarterly, 2025-12-31) — Basic EPS: -0.70
SYRE cash_flow (annual, 2025-12-31) — Beginning Cash Position: 89423000.00
SYRE cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 64897000.00
SYRE balance_sheet (annual, 2025-12-31) — Capital Stock: 155835000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Capital Stock: 155835000.00
SYRE balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 85721000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 85721000.00
SYRE balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 756533000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 756533000.00
SYRE cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 309025000.00
SYRE cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 312812000.00
SYRE cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -143475000.00
SYRE cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -247410000.00
SYRE cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -169252000.00
SYRE cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -44578000.00
SYRE cash_flow (annual, 2025-12-31) — Change In Account Payable: 7649000.00
SYRE cash_flow (quarterly, 2025-12-31) — Change In Account Payable: 858000.00
SYRE cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -764000.00
SYRE cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: 3124000.00
SYRE cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: 0.00
SYRE cash_flow (annual, 2025-12-31) — Change In Payable: 7649000.00
SYRE cash_flow (quarterly, 2025-12-31) — Change In Payable: -2509000.00
SYRE cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: 6885000.00
SYRE cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: 615000.00
SYRE cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -12819000.00
SYRE cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -2880000.00
SYRE cash_flow (annual, 2025-12-31) — Change In Receivables: 0.00
SYRE cash_flow (annual, 2025-12-31) — Change In Working Capital: -5934000.00
SYRE cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -2265000.00
SYRE cash_flow (annual, 2025-12-31) — Changes In Cash: -3702000.00
SYRE cash_flow (quarterly, 2025-12-31) — Changes In Cash: 20824000.00
SYRE balance_sheet (annual, 2025-12-31) — Common Stock: 15000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Common Stock: 15000.00
SYRE balance_sheet (annual, 2025-12-31) — Common Stock Equity: 559416000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 559416000.00
SYRE cash_flow (annual, 2025-12-31) — Common Stock Issuance: 311132000.00
SYRE cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 311132000.00
SYRE balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 18828000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 18828000.00
SYRE balance_sheet (annual, 2025-12-31) — Current Assets: 777781000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Current Assets: 777781000.00
SYRE balance_sheet (annual, 2025-12-31) — Current Liabilities: 58685000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 58685000.00
SYRE cash_flow (annual, 2025-12-31) — Depreciation: 0.00
SYRE cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 0.00
SYRE cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 0.00
SYRE income_statement (annual, 2025-12-31) — Diluted Average Shares: 64056442.00
SYRE income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 75088910.00
SYRE income_statement (annual, 2025-12-31) — Diluted EPS: -1.98
SYRE income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.70
SYRE income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -62530000.00
SYRE balance_sheet (annual, 2025-12-31) — Dueto Related Parties Current: 14000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Dueto Related Parties Current: 14000.00
SYRE income_statement (annual, 2025-12-31) — EBIT: -219562000.00
SYRE income_statement (quarterly, 2025-12-31) — EBIT: -57172000.00
SYRE income_statement (annual, 2025-12-31) — EBITDA: -219562000.00
SYRE income_statement (quarterly, 2025-12-31) — EBITDA: -57172000.00
SYRE cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 0.00
SYRE cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 0.00
SYRE cash_flow (annual, 2025-12-31) — End Cash Position: 85721000.00
SYRE cash_flow (quarterly, 2025-12-31) — End Cash Position: 85721000.00
SYRE cash_flow (annual, 2025-12-31) — Financing Cash Flow: 309025000.00
SYRE cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 312812000.00
SYRE cash_flow (annual, 2025-12-31) — Free Cash Flow: -169252000.00
SYRE cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -44578000.00
SYRE cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: -10000000.00
SYRE cash_flow (quarterly, 2025-12-31) — Gain Loss On Sale Of PPE: 0.00
SYRE income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: 10000000.00
SYRE income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 869000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 869000.00
SYRE income_statement (annual, 2025-12-31) — General And Administrative Expense: 47909000.00
SYRE income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 12534000.00
SYRE income_statement (annual, 2025-12-31) — Interest Income: 24885000.00
SYRE income_statement (quarterly, 2025-12-31) — Interest Income: 7139000.00
SYRE income_statement (annual, 2025-12-31) — Interest Income Non Operating: 24885000.00
SYRE income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 7139000.00
SYRE cash_flow (annual, 2025-12-31) — Interest Received Cfo: 2130000.00
SYRE cash_flow (quarterly, 2025-12-31) — Interest Received Cfo: 61000.00
SYRE balance_sheet (annual, 2025-12-31) — Invested Capital: 559416000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Invested Capital: 559416000.00
SYRE cash_flow (annual, 2025-12-31) — Investing Cash Flow: -143475000.00
SYRE cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -247410000.00
SYRE cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 311132000.00
SYRE cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 311132000.00
SYRE cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
SYRE cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 311132000.00
SYRE cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 311132000.00
SYRE income_statement (annual, 2025-12-31) — Net Income: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Income: -62530000.00
SYRE income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -62530000.00
SYRE income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -62530000.00
SYRE income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -62530000.00
SYRE income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -62530000.00
SYRE cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -155203000.00
SYRE cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -62530000.00
SYRE income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -155203000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -62530000.00
SYRE cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: 7000000.00
SYRE cash_flow (quarterly, 2025-12-31) — Net Intangibles Purchase And Sale: 0.00
SYRE income_statement (annual, 2025-12-31) — Net Interest Income: 24885000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Interest Income: 7139000.00
SYRE cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -150475000.00
SYRE cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -247410000.00
SYRE income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 24885000.00
SYRE income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 7139000.00
SYRE cash_flow (annual, 2025-12-31) — Net Other Financing Charges: -5413000.00
SYRE cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -69000.00
SYRE cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: 0.00
SYRE cash_flow (annual, 2025-12-31) — Net Preferred Stock Issuance: 0.00
SYRE cash_flow (quarterly, 2025-12-31) — Net Preferred Stock Issuance: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 715236000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 715236000.00
SYRE income_statement (annual, 2025-12-31) — Normalized EBITDA: -229562000.00
SYRE income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -57172000.00
SYRE income_statement (annual, 2025-12-31) — Normalized Income: -165202000.00
SYRE income_statement (quarterly, 2025-12-31) — Normalized Income: -62530000.00
SYRE cash_flow (annual, 2025-12-31) — Operating Cash Flow: -169252000.00
SYRE cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -44578000.00
SYRE cash_flow (annual, 2025-12-31) — Operating Gains Losses: -10000000.00
SYRE cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 0.00
SYRE income_statement (annual, 2025-12-31) — Operating Income: -219562000.00
SYRE income_statement (quarterly, 2025-12-31) — Operating Income: -57172000.00
SYRE income_statement (annual, 2025-12-31) — Operating Revenue: 0.00
SYRE income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 78189811.00
SYRE balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 78189811.00
SYRE balance_sheet (annual, 2025-12-31) — Other Current Assets: 21248000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 21248000.00
SYRE balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 22999000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 22999000.00
SYRE balance_sheet (annual, 2025-12-31) — Other Equity Adjustments: 869000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Other Equity Adjustments: 869000.00
SYRE income_statement (annual, 2025-12-31) — Other Gand A: 47909000.00
SYRE income_statement (quarterly, 2025-12-31) — Other Gand A: 12534000.00
SYRE income_statement (annual, 2025-12-31) — Other Income Expense: 39459000.00
SYRE income_statement (quarterly, 2025-12-31) — Other Income Expense: -12497000.00
SYRE cash_flow (annual, 2025-12-31) — Other Non Cash Items: -29769000.00
SYRE cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 12430000.00
SYRE balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 3860000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 3860000.00
SYRE income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 29459000.00
SYRE income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -12497000.00
SYRE balance_sheet (annual, 2025-12-31) — Other Short Term Investments: 670812000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 670812000.00
SYRE balance_sheet (annual, 2025-12-31) — Payables: 8918000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Payables: 8918000.00
SYRE balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 27746000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 27746000.00
SYRE balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 7940000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 7940000.00
SYRE balance_sheet (annual, 2025-12-31) — Preferred Stock: 155820000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 155820000.00
SYRE balance_sheet (annual, 2025-12-31) — Preferred Stock Equity: 155820000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Preferred Stock Equity: 155820000.00
SYRE cash_flow (annual, 2025-12-31) — Preferred Stock Issuance: 0.00
SYRE cash_flow (quarterly, 2025-12-31) — Preferred Stock Issuance: 0.00
SYRE income_statement (annual, 2025-12-31) — Pretax Income: -155218000.00
SYRE income_statement (quarterly, 2025-12-31) — Pretax Income: -62530000.00
SYRE cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 3306000.00
SYRE cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 1749000.00
SYRE cash_flow (annual, 2025-12-31) — Purchase Of Investment: -522214000.00
SYRE cash_flow (quarterly, 2025-12-31) — Purchase Of Investment: -341709000.00
SYRE income_statement (annual, 2025-12-31) — Reconciled Depreciation: 0.00
SYRE income_statement (annual, 2025-12-31) — Research And Development: 171653000.00
SYRE income_statement (quarterly, 2025-12-31) — Research And Development: 44638000.00
SYRE balance_sheet (annual, 2025-12-31) — Retained Earnings: -1127635000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -1127635000.00
SYRE cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
SYRE cash_flow (annual, 2025-12-31) — Sale Of Intangibles: 7000000.00
SYRE cash_flow (quarterly, 2025-12-31) — Sale Of Intangibles: 0.00
SYRE cash_flow (annual, 2025-12-31) — Sale Of Investment: 371739000.00
SYRE cash_flow (quarterly, 2025-12-31) — Sale Of Investment: 94299000.00
SYRE cash_flow (annual, 2025-12-31) — Sale Of PPE: 0.00
SYRE income_statement (annual, 2025-12-31) — Selling General And Administration: 47909000.00
SYRE income_statement (quarterly, 2025-12-31) — Selling General And Administration: 12534000.00
SYRE balance_sheet (annual, 2025-12-31) — Share Issued: 78189811.00
SYRE balance_sheet (quarterly, 2025-12-31) — Share Issued: 78189811.00
SYRE income_statement (annual, 2025-12-31) — Special Income Charges: 10000000.00
SYRE income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
SYRE cash_flow (annual, 2025-12-31) — Stock Based Compensation: 37614000.00
SYRE cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 9811000.00
SYRE balance_sheet (annual, 2025-12-31) — Stockholders Equity: 715236000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 715236000.00
SYRE balance_sheet (annual, 2025-12-31) — Tangible Book Value: 559416000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 559416000.00
SYRE income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: 1000.00
SYRE income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
SYRE income_statement (annual, 2025-12-31) — Tax Provision: -15000.00
SYRE income_statement (quarterly, 2025-12-31) — Tax Provision: 0.00
SYRE income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.00
SYRE income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
SYRE balance_sheet (annual, 2025-12-31) — Total Assets: 777781000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Total Assets: 777781000.00
SYRE balance_sheet (annual, 2025-12-31) — Total Capitalization: 715236000.00
SYRE balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 715236000.00
SYRE balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 715236000.00